Abstract
In Latin America and the Caribbean, more than 70% of the 52 countries and territories have introduced pneumococcal conjugate vaccines (PCVs) into their national immunisation programmes for infants. More than 73 million children live in the region, and, as of 2018, about 82% had received at least three doses of PCV.1 Many reports have described the benefits of PCVs in North America,2,3 with recent evidence showing these findings in the Latin American and Caribbean countries.4,5 In The Lancet Infectious Diseases, Clara Inés Agudelo and colleagues' observational study6 reports data from the Sistema Regional de Vacunas (SIREVA) network.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
